异丙托溴铵联合沙美特罗替卡松治疗老年慢性阻塞性肺疾病的效果分析

Effect of Ipratropium Bromide Combined with Salmeterol Ticarcoson in Treating Chronic Obstructive Pulmonary Disease in the Elderly

目的:探讨异丙托溴铵联合沙美特罗替卡松治疗老年慢性阻塞性肺疾病的临床效果。方法:选取2021年11月—2022年10月单县中心医院收治的老年慢性阻塞性肺疾病患者70例作为研究对象,根据随机数字表法分为两组,各35例。参考组采用沙美特罗替卡松治疗,研究组在参考组基础上采用异丙托溴铵治疗,比较两组治疗效果。结果:治疗前,两组用力肺活量(FVC)、最大呼吸流量(PEF)、第1秒用力呼气容积(FEV1)比较,差异无统计学意义(P>0.05);治疗后,两组FVC、PEF、FEV1均高于治疗前,且研究组高于参考组,差异有统计学意义(P<0.05)。治疗前,两组白细胞介素-8(IL-8)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平比较,差异无统计学意义(P>0.05);治疗后,两组IL-8、IL-6、TNF-α水平均低于治疗前,且研究组低于参考组,差异有统计学意义(P<0.05)。治疗前,两组血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))、血氧饱和度(SaO_(2))水平比较,差异无统计学意义(P>0.05);治疗后,两组PaO_(2)、SaO_(2)高于治疗前,且研究组高于参考组,两组PaCO_(2)低于治疗前,且研究组低于参考组,差异有统计学意义(P<0.05)。研究组咳痰、咳嗽缓解时间,住院时间均短于参考组,差异有统计学意义(P<0.05)。结论:异丙托溴铵联合沙美特罗替卡松治疗老年慢性阻塞性肺疾病的效果显著,能够改善患者肺功能、血气分析指标与症状,降低炎性因子水平,加速康复。

Objective:To explore the therapeutic effect of ipratropium bromide combined with salmeterol ticarcoson in the treatment of chronic obstructive pulmonary disease in the elderly.Methods:70 cases of elderly patients with chronic obstructive pulmonary disease admitted to Shanxian Central Hospital from November 2021 to October 2022 were selected as the study subjects,and were divided into two groups of 35 cases each according to the randomized numerical table method.The reference group was treated with salmeterol ticarcoson,and the study group was treated with ipratropium bromide on the basis of the control group,and the therapeutic effects of the two groups were compared.Results:Forced Vital Capacity(FVC),Peak Expiratory Flow(PEF),and forced Expiratory Volume in the first second(FEV1)between the two groups before treatment was not statistically significant(P>0.05);however,FVC,PEF,and FEV1 after treatment were higher than those before treatment in both groups,and the research group was higher than that of the reference group,and the difference was statistically significant(P<0.05).Before treatment the levels of interleukin-8(IL-8),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)in the two groups were compared,and the difference was not statistically significant(P>0.05);the levels of IL-8,IL-6,and TNF-αafter treatment in both groups were lower than those before treatment,and the study group was lower than the reference group,and the difference was statistically significant(P<0.05).Before treatment,the levels of partial pressure of blood oxygen(PaO_(2)),partial pressure of arterial blood carbon dioxide(PaCO_(2)),and blood oxygen saturation(SaO_(2))were compared between the two groups,and the difference was not statistically significant(P>0.05);after treatment the levels of PaO_(2)and SaO_(2)were higher than those before treatment in both groups,and the research group was higher than that of the reference group,while the levels of PaCO_(2)were lower than those before treatment in the two groups,and the research group was lower than that of the reference group,and the difference was statistically significant(P<0.05).The sputum and cough relief time and hospitalization duration of the study group were shorter than that of the reference group,and the difference was statistically significant(P<0.05).Conclusion:The effect of ipratropium bromide combined with salmeterol ticarcoson in the treatment of chronic obstructive pulmonary disease in the elderly is remarkable,and it can improve patients'lung function,blood gas analysis indexes and symptoms,reduce the level of inflammatory factors,and accelerate recovery.